RT Journal Article
SR Electronic
T1 High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20028407
DO 10.1101/2020.03.05.20028407
A1 Tagai, Kenji
A1 Ono, Maiko
A1 Kubota, Manabu
A1 Kitamura, Soichiro
A1 Takahata, Keisuke
A1 Seki, Chie
A1 Takado, Yuhei
A1 Shinotoh, Hitoshi
A1 Sano, Yasunori
A1 Matsuoka, Kiwamu
A1 Takuwa, Hiroyuki
A1 Shimojo, Masafumi
A1 Takahashi, Manami
A1 Kawamura, Kazunori
A1 Kikuchi, Tatsuya
A1 Okada, Maki
A1 Akiyama, Haruhiko
A1 Suzuki, Hisaomi
A1 Onaya, Mitsumoto
A1 Takeda, Takahiro
A1 Arai, Kimihito
A1 Arai, Nobutaka
A1 Araki, Nobuyuki
A1 Saito, Yuko
A1 Kimura, Yasuyuki
A1 Ichise, Masanori
A1 Tomita, Yutaka
A1 Zhang, Ming-Rong
A1 Suhara, Tetsuya
A1 Shigeta, Masahiro
A1 Sahara, Naruhiko
A1 Higuchi, Makoto
A1 Shimada, Hitoshi
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.03.05.20028407.abstract
AB A panel of radiochemicals has enabled in-vivo positron emission tomography (PET) of tau pathologies in Alzheimer’s disease (AD), while sensitive detection of frontotemporal lobar degeneration (FTLD) tau inclusions has been unsuccessful. Here, we generated an imaging probe, PM-PBB3, for capturing diverse tau deposits. In-vitro assays demonstrated the reactivity of this compound with tau pathologies in AD and FTLD. We could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model. A subsequent clinical PET study revealed increased binding of 18F-PM-PBB3 in diseased patients, reflecting cortical-dominant AD and subcortical-dominant PSP tau topologies. Notably, the in-vivo reactivity of 18F-PM-PBB3 with FTLD tau inclusion was strongly supported by neuropathological examinations of autopsied and biopsied brains derived from Pick’s disease, PSP and corticobasal degeneration patients who underwent PET scans. Finally, visual inspection of 18F-PM-PBB3-PET images was indicated to facilitate individually based identification of diverse clinical phenotypes of FTLD on the neuropathological basis.Competing Interest StatementM-R. Zhang, T. Suhara, M. Higuchi, and H. Shimada hold a patent on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). All the other authors have no potential conflicts of interest to be disclosed.Clinical TrialUMIN-CTR; number 000030248Funding StatementThis study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049 to M. H., and by MEXT KAKENHI Grant Number JP16H05324 to M. H., JP18K07543 to H. Shimada, JP26117011 to N. S., and by JST CREST Grant Number JPMJCR1652 to M. Higuchi.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.